2026-01-29 - Analysis Report
**Company Overview**
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for serious diseases, including eye diseases, cancer and infectious diseases.

**Return Rate Comparison**
Cumulative return of review stock (REGN): 53.78%
Cumulative return of comparison stock (S&P 500, VOO): 128.51%
Divergence: The cumulative return of REGN is -74.70, which is a relatively large divergence from the S&P 500.

**Alpha, Beta Analysis**
| Year      | CAGR | MDD | Alpha | Beta | Cap(B) |
|-----------|------|-----|-------|------|--------|
| 2016-2018 | -3.0%| 24.1% | -12.0% | 1.2 | 38.7B  |
| 2017-2019 | 9.0% | 27.3% | -16.0% | 1.0 | 38.9B  |
| 2018-2020 | 31.0%| 27.3% | 7.0%  | 0.7 | 50.1B  |
| 2019-2021 | 40.0%| 27.3% | -25.0% | 0.6 | 65.5B  |
| 2020-2022 | 72.0%| 25.7% | 68.0% | 0.6 | 74.8B  |
| 2021-2023 | 61.0%| 24.4% | 43.0% | 0.6 | 91.0B  |
| 2022-2024 | -1.0%| 40.5% | -30.0% | 0.6 | 73.8B  |
| 2023-2025 | -17.0%| 57.2% | -92.0% | 0.6 | 80.0B  |

**Recent Stock Price Fluctuations**
* Close: $771.25
* Last-market: $753.595
* 5-day SMA: $758.46
* 20-day SMA: $766.72
* 60-day SMA: $736.05

**RSI, PPO, Delta_Previous_Relative_Divergence, Expected_Return Analysis**
- Market Risk Indicator (MRI): 0.70
- RSI: 48.32
- PPO: -0.30
- Risk Level: Medium
- Recent relative divergence change: improving
- 7-day Rank change: rank up
- 7-day Dynamic Expected Return change: improving
- Expected Return: 5.50%

**Recent News & Significant Events**

* Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? - TradingView (news.google.com)
* Federated Hermes Inc. Has $132.81 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat (news.google.com)
* Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts - Yahoo Finance (news.google.com)
* A big Wall Street flip just changed the Regeneron narrative - thestreet.com (news.google.com)
* REGN or ILMN: Which Is the Better Value Stock Right Now? - Nasdaq (news.google.com)
* Amgen Set to Report Q4 Earnings: What Investors Should Know - The Globe and Mail (news.google.com)

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 831.38 / 1057.00 / 630.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|------|-----|----------|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

**Revenue and Profitability Analysis**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

**Capital and Profitability Analysis**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

**Comprehensive Analysis**
Based on the data provided, Regeneron Pharmaceuticals, Inc. has seen a 53.78% cumulative return in the recent past, which is divergent from the S&P 500's 128.51% cumulative return. The company's Alpha, Beta analysis shows a mix of performances across different periods. The recent stock price fluctuations indicate a decline in the stock price, but the moving averages suggest a potential rebound. The RSI and PPO indicators suggest a neutral market risk, while the hybrid signal indicates a medium risk level. The analyst opinions are generally positive, with a mean rating of 1.69 and a target price of around $831. The company's revenue and profitability have seen an increase across different periods, with a profit margin ranging from 84.67% to 86.80%. Overall, the company's performance and outlook suggest a medium-risk investment opportunity.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.